Discover Clinical Trials at City of Hope
Use the search and filter features below to discover and explore relevant clinical trials underway at City of Hope®. Please reach out to your cancer care team who can help you find out whether you qualify for any of our open clinical trials.
465 results
Investigating the Feasibility of L-theanine in Supporting Relaxation and Mood in Cancer Survivors Undergoing Surveillance
This clinical trial tests the feasibility, best dose, and effectiveness of L-theanine for supporting relaxation and mood among cancer patients in surveillance. L-theanine is a substance found in the leaves of green tea with potential to enhance mental health and well-being. It works by increasing certain chemicals within the body that have been associated with stress reduction, mood stabilization, and improved cognitive performance.
Location Name
Status
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
A Phase III, Randomized, Open-Label, Multicenter Study of Datopotamab deruxtecan or Docetaxel in Previously Treated TROP2 Biomarker Positive Advanced or Metastatic Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (D763QC00001)
TROPION-Lung17 will measure the efficacy and safety of datopotamab deruxtecan (Dato-DXd) compared with docetaxel in patients with trophoblast cell surface protein 2 (TROP2) positive advanced or metastatic lung cancer without actionable genomic alterations (AGA).
Location Name
Status
Antelope Valley
Suspended
Atlanta
Open to Accrual
Chicago
Open to Accrual
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
Phoenix
Open to Accrual
A Phase 1b/2a, Randomized, Double-blind Study to Investigate Safety, Tolerability, PK, PD, and Preliminary Efficacy of Oral Administration of SNIPR001 in Patients with Hematologic Malignancy Scheduled for Allogeneic Hematopoietic Stem-Cell Transplantation Receiving Fluoroquinolone Prophylaxis and Harboring Fluoroquinolone-Resistant Escherichia coli Pre-Transplant
This is a Phase 1b/2a study in allogenic hematopoietic stem cell transplant patients to investigate the safety, PK, PD and preliminary efficacy of multiple oral administrations of SNIPR001 when given concomitantly with SoC levofloxacin. The study consists of two parts. Part 1 will include 24 randomized and dosed patients. Part 2 will be added with amendment 3 and will include 42 randomized and dosed patients. Thus, approximately 66 patients will be randomized 1:1 to oral dosing of SNIPR001 or matching placebo, to be taken concomitantly with SoC levofloxacin prophylaxis. Subjects will be followed until 100 days post allo-HSCT transplant.
Location Name
Status
Duarte
Open to Accrual
Geriatric Assessment and Management for Older Adults Undergoing Radiation Therapy for Head and Neck Cancer and their Family Caregivers
This clinical trial compares the effect of geriatric assessment (GA)-based management of supportive care to usual care in treating older patients undergoing chemotherapy and radiation therapy for head and neck cancer and their family caregivers (FCG). At least one quarter of head and neck cancers patients are diagnosed at age 70 or older. Treatment for head and neck cancers usually include surgery, chemotherapy, and radiation. Older adults are often at higher risk for functional problems, and may experience more side effects. In addition, there may be a lack of support mechanisms in place to address the needs of these older patients. Cancer not only affects the patients but the entire family, especially the family member who is the caregiver. Currently, all patients over 65 receive the same standard of care based on national guidelines, which include supportive care referrals. However, data suggests, that many patients may need more frequent and structured support. The Practical Geriatric Assessment (PGA) is a complete examination including evaluation of the physical and mental function as well as the emotional state of the older patient. PGA-based supportive care interventions may be safe, tolerable, and/or effective in managing treatment-related side effects and improving quality of life compared to usual care in older patients undergoing chemotherapy and radiation therapy for head and neck cancer and their FCG.
Location Name
Status
Antelope Valley
Open to Accrual
Arcadia
Open to Accrual
Corona
Open to Accrual
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
South Bay
Open to Accrual
South Pasadena
Open to Accrual
Upland
Open to Accrual
A Phase 1 Study of the Polymerase Theta (POL0) Inhibitor Novobiocin in BRCA- mutant and Other DNA Damage Repair-Deficient Solid Tumors
This phase I trial tests the safety, side effects, and best dose of novobiocin in treating cancer patients with alterations in deoxyribonucleic acid (DNA) repair genes. Novobiocin is an antibiotic that blocks the activity of a protein called DNA polymerase theta, which helps repair DNA that has become damaged as cells grow and divide. Cancer cells that cannot repair their damaged DNA die. This medication may help shrink or stabilize cancer with a mutation in DNA repair genes.
Location Name
Status
Duarte
Open to Accrual
CCTG-HN11: SPECT-CT Guided Elective Contralateral Neck Treatment (Select) For Patients with Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial
This study is being done to answer the following question:
Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck?
Is the chance of cancer spreading or returning the same if radiotherapy to the neck is guided, by using a special imaging study called lymph node mapping (lymphatic mapping) Single Photon Emission Computed Tomography (SPECT-CT), compared to the usual treatment when radiotherapy is given to both sides of the neck?
Location Name
Status
Antelope Valley
Pending
Corona
Open to Accrual
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
South Bay
Pending
A Phase III Study of Induction Pembrolizumab and Chemotherapy Followed by Chemoradiation and Pembrolizumab Vs Chemoradiation and Pembrolizumab Both Followed by Pembrolizumab for High Risk Locally Advanced Cervical Cancer
This phase III trial compares the addition of induction chemotherapy, with carboplatin, paclitaxel and pembrolizumab, to chemotherapy and radiation, with cisplatin and pembrolizumab followed by pembrolizumab maintenance for the treatment of patients with cervical cancer that has spread to nearby tissue or lymph nodes (locally advanced). Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Paclitaxel is in a class of medications called antimicrotubule agents. It stops cancer cells from growing and dividing and may kill them. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Cisplatin is in a class of medications known as platinum-containing compounds. It works by killing, stopping or slowing the growth of cancer cells. Adding induction chemotherapy to the usual treatment of chemotherapy and radiation followed by maintenance may be more effective in treating patients with high risk, locally advanced cervical cancer.
Location Name
Status
Antelope Valley
Closed to Accrual
Atlanta
Open to Accrual
Chicago
Open to Accrual
Corona
Open to Accrual
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
Seacliff
Closed to Accrual
South Pasadena
Open to Accrual
Upland
Open to Accrual
A Phase 3, Multicenter, Randomized, Open-Label, Study Evaluating the Efficacy and Safety of Nanvuranlat in Patients with Previously Treated Advanced Biliary Tract Cancer
This study is designed to 1) select a dose regimen for continued development and 2) evaluate nanvuranlat versus Physicians Best Choice (PBC) (FOLFOX, FOLFIRI, or Best Supportive Care (BSC)) in participants aged 18 years and over with BTC. Participants enrolling in Part A the trial will be randomly assigned to receive 1 of 3 nanvuranlat dose regimens or PBC. In Part B, participants will be randomly assigned to receive nanvuranlat or PBC. Participants will receive treatment every 2 weeks for as long as they do not experience safety issues, or their cancer gets worse, and the study doctor feels they should stop treatment. Health measurements including physical examinations, vital signs, ECGs, and safety laboratory tests will be performed to monitor safety, and tumor imaging will be performed to monitor cancer response to treatment. Other exploratory makers will be measured to better understand how nanvuranlat works.
Location Name
Status
Atlanta
Closed to Accrual
Chicago
Open to Accrual
Duarte
Open to Accrual
FONTANA: A Modular Phase I/IIa, Open-label, Multi-centerStudy to Assess the Safety, Tolerability, Pharmacokinetics, andPreliminary Efficacy of Ascending Doses of AZD5335Monotherapy and in Combination with Anti-cancer Agents inParticipants with Solid Tumors
This research is designed to determine if experimental treatment with Antibody-drug conjugate, AZD5335, alone, or in combination with anti-cancer agents is safe, tolerable, and has anti-cancer activity in patients with advanced tumors
Location Name
Status
Duarte
Open to Accrual
Lennar Foundation Cancer Center
Open to Accrual
Phase 2, Open Label, Multicenter Dtudy of Pacritinib in Telapsed/Tefractory T-cell Lymphoproliferative Neoplasms
The main purpose of this study is to determine the effectiveness of the study drug pacritinib in people with relapsed or refractory lymphoproliferative disorders.
Location Name
Status
Duarte
Suspended
Lennar Foundation Cancer Center
Suspended
Note: Some clinical trials at City of Hope may not be listed. Please reach out to your cancer care team to identify additional trials for which you may qualify.